Tafnat 25 MG

Discount 5.00 USD

45.00 USD
- +

Drug profile for Tafnat tablet

Tafnat tablets are primarily used in hepatitis infection condition, is in chronic stage.

Tafnat tablets are only used by the patients who are having a valid prescription

Tafnat tablets are containing an anti-viral agent known as Tenofovir Alafenamide which may not cure the infection but may suppress the growth of virus.

Trade name: Tafnat

Active component: Tenofovir Alafenamide

Strength: 25mg

Mfg: Mylan pharmaceuticals

Pack: 30 tablets in a container

Category: Anti-hepaciviral activity

Prescribing information of Tafnat

The most frequently used anti-viral agent like Tenofovir Alafenamide is primarily indicated for the treatment of chronic hepatitis B viral infection occurred in adults patient with compensated liver damage.

Mechanism of Tafnat

Tafnat worked in the body by some component incorporates;

For the most part Tafnat containing tenofovir Alafenamide is a prodrug which is changed over into dynamic frame in-vivo

Tenofovir Alafenamide has cell penetrability property which is lipophilic in nature, infiltrates into hepatocytes by latent dissemination strategy and additionally by hepatic return transporters OATP1B1 and OATP1B3

In-vivo, tenofovir Alafenamide is changed into tenofovir a parent compound by experiencing hydrolysis with the chemical carboxylesterase 1 which is happen in hepatocytes cell

This dynamic frame tenofovir is phosphorylated into tenofovir diphosphate by cell kinase compounds

TAF has pharmacologically dynamic compound known as tenofovir diphosphate which is in charge of viral multiplication denial by means of imbuing into infection DNA with the assistance of turnaround transcriptase chemical which causes viral DNA chain end


Maximum plasma concentration time of TAF 0.48 hours


TAF is largely bound to human plasma protein at 80%

Protein binding data occurs in vivo

The blood plasma ratio of TAF is 1.0


The metabolism of TAF occurs with the help of;

Carboxyl esterase 1

Cathepsin A



Nearly 80% of TAF get metabolized and reaches its half life at 0.51 hour

<1% of metabolite released through urine

31.7% excreted via feces

When to take the Tafnat tablets

Tafnat tablets should be taken with food

Dosage regimens of Tafnat

Before initiate the treatment with Tafnat tablets, patients must be investigate whether they are suspected with HIV 1 infection or not.

The suggested dosage of Tafnat is 25mg should be administered as a single dose.

In both mild to moderate liver and kidney impaired patients, dosage adjustment should not be allowed; whereas severe conditions, Tafnat not recommended.

Tafnat caused side effects

The most serious adverse effects;

Serious exacerbation of hepatitis B infection

Out breaking or worsening of renal damage

Lactic acidosis

Hepatomegaly with steatosis

Common side effects;




Back pain


Abdominal pain

Loss of bone mineral density


Increase in lipase & amylase

Increasing in serum lipids

Drug- drug interaction of Tafnat

Tafnat tablets with P-gp or BCRP inhibiting drugs, causes variation in absorption of TAF; this may leads to adverse effects.

Tafnat tablets with P gp or BCRP inducing drugs causes depletion of absorption of TAF leads to increasing the concentration of TAF

Tafnat tablets with renal function reducing drugs may leads to increasing the concentration and causes serious adverse effects

Tafnat tablet combined with anti-convulsants leads to decreasing the effect of concentration of TAF

Tafnat tablet combined with anti-mycobacterials causes reducing the effect of concentration of TAF

Tafnat tablets concomitant use of herbal product like st, John’s wort, causes decreasing the TAF concentration.

Food drug interaction of Tafnat;

Minor food drug interaction may occur; alcohol containing food items should not be suggested.

Consult with physician about the dietary.

Possible contraindications of Tafnat

No specific contraindication occurs, if some patients may contraindicate to TAF causes anaphylactic reactions.

Safety measures

Aggravation of hepatitis B infection: Check the patient history before starting the treatment

Exposure of advancement of HIV-1 resistance: Due to this condition, Tafnat tablets are not suggested for HIV-1 infections

New commencement of renal damage: To avoid concomitant use of Tafnat with renal function depleting drugs

Lactic acidosis or hepatomegaly with steatosis: Stop the therapy with Tafnat

Pregnancy and lactation

Tafnat tablets are probably used in pregnancy conditions, only after knowing the risk of the product associated to fetus.

Breast feeding should not be suggested.

Storage and handling

Tafnat tablet container should be kept at below 30oC

Protect the container from heat, moisture & heat

Missed dose

In case of missed dose, get advice from medical practitioner and their instruction; otherwise avoid the missed dose and follow the regular schedule.

Over dosage

If over dosage occurs during the therapy;

Provide the patients with supportive measures

Monitor the signs & symptoms

Hemodialysis is done, to eliminate the TAF content with the range of 54%.


    No comments yet
Write a comment
Your name
Your name

Sale of day

Choice of buyers. Only popular options!Choice of buyers.
Only popular options!

view all
Dr. Reddy’s
  • Children born with HIV
    Children born with HIV
    Children born with HIV accessing treatment, have no significant difference in their movement skills, social interaction, language skills or practical reasoning at age five compared to HIV-negative children, according to new research....